Atopic dermatitis: The role of Langerhans cells in disease pathogenesis

Immunology and Cell Biology

Volumn 88, Issue 4, 2010, Pages 400-409

  Dubrac, Sandrine ^a   Schmuth, Matthias ^a   Ebner, Susanne ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b K1 Center Oncotyrol   (Austria)

Author keywords

Atopic dermatitis; FceRI; Langerhans cells; Mouse models; TSLP; TSLPR

Indexed keywords

ALLERGEN; CD86 ANTIGEN; FILAGGRIN; HAPTEN; IMMUNOGLOBULIN E;

ATOPIC DERMATITIS; CELL FUNCTION; CELL STRUCTURE; DENDRITIC CELL; DISEASE MODEL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EOSINOPHIL; GENETIC ENGINEERING; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; LANGERHANS CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CELL; SKIN FUNCTION; SKIN INFLAMMATION; STRESS;

ANIMALS; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; HUMANS; LANGERHANS CELLS;

EID: 77952237328     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.33     Document Type: Review

References (85)

1. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.
2. Hanifin JM. Evolving concepts of pathogenesis in atopic dermatitis and other eczemas. J Invest Dermatol 2009; 129: 320-322.
3. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657.
4. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009; 129: 14-30.
5. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870-876.
6. Novak N, Kraft S, Bieber T. Unraveling the mission of FceRI on antigen-presenting cells. J Allergy Clin Immunol 2003; 111: 38-44.
7. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111: 875-881.
8. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol 2009; 9: 437-446.
9. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
10. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 2007; 39: 650-654.
11. Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009; 41: 602-608.
12. Oyoshi MK, Murphy GF, Geha RS. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol 2009; 124: 485 .
13. Scharschmidt TC, Man MQ, Hatano Y, Crumrine D, Gunathilake R, Sundberg JP et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol 2009; 124: 496 .
14. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.
15. Gao PS, Rafaels NM, Hand T, Murray T, Boguniewicz M, Hata T et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 2009; 124: 507.
16. Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000; 105: 814-819.
17. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998; 101: 1614-1622.
18. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009; 124: R7-R12.
19. Oyoshi MK, He R, Kumar L, Yoon J, Geha RS. Cellular and molecular mechanisms in atopic dermatitis. Adv Immunol 2009; 102: 135-226.
20. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol 2009; 129: 31-40.
21. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005; 202: 541-549.
22. Chappaz S, Flueck L, Farr AG, Rolink AG, Finke D. Increased TSLP availability restores T- and B-cell compartments in adult IL-7 deficient mice. Blood 2007; 110: 3862-3870.
23. Li M, Messaddeq N, Teletin M, Pasquali J-L, Metzger D, Chambon P. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci USA 2005; 102: 14795-14800.
24. Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand Hammarström B et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol 2002; 118: 444-449.
25. Judge MR, Morgan G, Harper JI. A clinical and immunological study of Netherton's syndrome. Br J Dermatol 1994; 131: 615-621.
26. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009; 206: 1135-1147.
27. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 2009; 129: 742-751.
28. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001; 117: 977-983.
29. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, Chan LS. Early upregulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 2004; 138: 375-387.
30. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-760.
31. Tsukuba T, Okamoto K, Okamoto Y, Yanagawa M, Kohmura K, Yasuda Y et al. Association of cathepsin E deficiency with development of atopic dermatitis. J Biochem 2003; 134: 893-902.
32. Tsukuba T, Yamamoto S, Yanagawa M, Okamoto K, Okamoto Y, Nakayama KI et al. Cathepsin E-deficient mice show increased susceptibility to bacterial infection associated with the decreased expression of multiple cell surface Toll-like receptors. J Biochem 2006; 140: 57-66.
33. Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008; 128: 79-86.
34. Woodward AL, Spergel JM, Alenius H, Mizoguchi E, Bhan AK, Castigli E et al. An obligate role for T-cell receptor alphabeta+ T cells but not T-cell receptor gammadelta+ T cells, B cells, or CD40/CD40L interactions in a mouse model of atopic dermatitis. J Allergy Clin Immunol 2001; 107: 359-366.
35. Alenius H, Laouini D, Woodward A, Mizoguchi E, Bhan AK, Castigli E et al. Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergeninduced skin inflammation. J Allergy Clin Immunol 2002; 109: 106-113.
36. Elkhal A, Pichavant M, He R, Scott J, Meyer E, Goya S et al. CD1d restricted natural killer T cells are not required for allergic skin inflammation. J Allergy Clin Immunol 2006; 118: 1363-1368.
37. Li M, Hener P, Zhang Z, Kato S, Metzger D, Chambon P. Topical vitamin D3 and lowcalcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 2006; 103: 11736-11741.
38. Li M, Hener P, Zhang Z, Ganti KP, Metzger D, Chambon P. Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J Invest Dermatol 2009; 129: 498-502.
39. Matsumoto M, Ra C, Kawamoto K, Sato H, Itakura A, Sawada J et al. IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J Immunol 1999; 162: 1056-1063.
40. Sumiyoshi K, Nakao A, Ushio H, Mitsuishi K, Okumura K, Tsuboi R et al. Transforming growth factor-beta1 suppresses atopic dermatitis-like skin lesions in NC/Nga mice. Clin Exp Allergy 2002; 32: 309-314.
41. Sasakawa T, Higashi Y, Sakuma S, Hirayama Y, Sasakawa Y, Ohkubo Y et al. Topical application of FK506 (tacrolimus) ointment inhibits mite antigen-induced dermatitis by local action in NC/Nga mice. Int Arch Allergy Immunol 2004; 133: 55-63.
42. Sugimoto M, Arai I, Futaki N, Hashimoto Y, Sakurai T, Honma Y et al. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice. Eur J Pharmacol 2007; 564: 196-203.
43. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997; 9: 461-466.
44. Sasakawa T, Higashi Y, Sakuma S, Hirayama Y, Sasakawa Y, Ohkubo Y et al. Atopic dermatitis-like skin lesions induced by topical application of mite antigens in NC/Nga mice. Int Arch Allergy Immunol 2001; 126: 239-247.
45. Aioi A, Tonogaito H, Suto H, Hamada K, Ra CR, Ogawa H et al. Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis. Br J Dermatol 2001; 144: 12-18.
46. Hikita I, Yoshioka T, Mizoguchi T, Tsukahara K, Tsuru K, Nagai H et al. Characterization of dermatitis arising spontaneously in DS-Nh micemaintained under conventional conditions: another possible model for atopic dermatitis. J Dermatol Sci 2002; 30: 142-153.
47. Haraguchi M, Hino M, Tanaka H, Maru M. Naturally occurring dermatitis associated with Staphylococcus aureus in DS-Nh mice. Exp Anim 1997; 46: 225-229.
48. Elentner A, Finke D, Schmuth M, Chappaz S, Ebner S, Malissen B et al. Langerhans cells are critical in the development of atopic dermatitis-like inflammation and symptoms in mice. J Cell Mol Med 2009; 13: 2658-2672.
49. Kissenpfennig A, Henri S, Dubois B, Laplace-Builhé C, Perrin P, Romani N et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005; 22: 643-654.
50. Kissenpfennig A, Malissen B. Langerhans cells-revisiting the paradigm using genetically engineered mice. Trends Immunol 2006; 27: 132-139.
51. Chorro L, Sarde A, Li M, Woollard KJ, Chambon P, Malissen B et al. LC proliferation mediates neonatal development, homeostasis, and inflammationassociated expansion of the epidermal LC network. J Exp Med 2009; 206: 3089-3100.
52. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992; 90: 482-487.
53. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol 1997; 109: 175-182.
54. Pastore S, Mascia F, Girolomoni G. The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol 2006; 16: 125-131.
55. Tada Y, Asahina A, Nakamura K, Tomura M, Fujiwara H, Tamaki K. Granulocyte/ macrophage colony-stimulating factor inhibits IL-12 production of mouse Langerhans cells. J Immunol 2000; 164: 5113-5119.
56. Holzmann S, Tripp CH, Schmuth M, Janke K, Koch F, Saeland S et al.Amodel system using tape stripping for characterization of Langerhans cell-precursors in vivo. J Invest Dermatol 2004; 122: 1165-1174.
57. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 2004; 34: 2100-2109.
58. Strid J, Callard R, Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology 2006; 119: 27-35.
59. Sano S, Nakajima K, Terao M, Takaishi M, Azukizawa H, Katayama I et al. Ceramide deficiency in epidermis results in development of dermatitis through Langerhans cell maturation and expansion of IL-17-producing gamma/delta T cells. 49th Annual ESDR (European Society for Dermatological Research) Meeting, 2009. Poster 024.
60. Matsui K, Wirotesangthong M, Nishikawa A. Percutaneous application of peptidoglycan from Staphylococcus aureus induces eosinophil infiltration in mouse skin. Clin Exp Allergy 2007; 37: 615-622.
61. Szegedi A, Barath S, Nagy G, Szodoray P, Gál M, Sipka S et al. Regulatory T cells in atopic dermatitis: epidermal dendritic cell clusters may contribute to their local expansion. Br J Dermatol 2009; 160: 984-993.
62. Ito Y, Adachi Y, Makino T, Higashiyama H, Fuchizawa T, Shimizu T et al. Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis. Ann Allergy Asthma Immunol 2009; 103: 160-165.
63. Taylor AL, Hale J, Hales BJ, Dunstan JA, Thomas WR, Prescott SL. FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth. Pediatr Allergy Immunol 2007; 18: 10-19.
64. Caproni M, Antiga E, Torchia D, Volpi W, Barletta E, Gitti G et al. FoxP3-expressing T regulatory cells in atopic dermatitis lesions. Allergy Asthma Proc 2007; 28: 525-528.
65. Senechal B, Elain G, Jeziorski E, Grondin V, Patey-Mariaud de Serre N, Jaubert F et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007; 4: e253; 1374-1384.
66. Igyarto BZ, Jenison MC, Dudda JC, Roers A, Müller W, Koni PA et al. Langerhans cells suppress contact hypersensitivity responses via cognate CD4 interaction and langerhans cell-derived IL-10. J Immunol 2009; 183: 5085-5093.
67. Yoshiki R, Kabashima K, Sugita K, Atarashi K, Shimauchi T, Tokura Y. IL-10- producing Langerhans cells and regulatory T cells are responsible for depressed contact hypersensitivity in grafted skin. J Invest Dermatol 2009; 129: 705-713.
68. Schwarz A, Maeda A, Schwarz T. Alteration of the migratory behavior of UV-induced regulatory T cells by tissue-specific dendritic cells. J Immunol 2007; 178: 877-886.
69. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12: 1372-1379.
70. Ohki O, Yokozeki H, Katayama I, Umeda T, Azuma M, Okumura K et al. Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis. Br J Dermatol 1997; 136: 838-845.
71. Schuller E, Teichmann B, Haberstok J, Moderer M, Bieber T, Wollenberg A. In situ expression of the costimulatory molecules CD80 and CD86 on Langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis. Arch Dermatol Res 2001; 293: 448-454.
72. Ritprajak P, Hashiguchi M, Azuma M. Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther 2008; 16: 1323-1330.
73. Saint-Mezard P, Chavagnac C, Bosset S, Ionescu M, Peyron E, Kaiserlian D et al. Psychological stress exerts an adjuvant effect on skin dendritic cell functions in vivo. J Immunol 2003; 171: 4073-4080.
74. Kawaguchi Y, Okada T, Konishi H, Fujino M, Asai J, Ito M. Reduction of the DTH response is related to morphological changes of Langerhans cells in mice exposed to acute immobilization stress. Clin Exp Immunol 1997; 109: 397-401.
75. Bruynzeel-Koomen C, van Wichen DF, Toonstra J, Berrens L, Bruynzeel PLB. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 1986; 278: 199-205. (Pubitemid 16106518)
76. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP et al. The high affinity IgE receptor (FceRI) mediates IgE-dependent allergen presentation. J Immunol 1995; 154: 6285-6290.
77. Klubal R, Osterhoff B, Wang BH, Kinet JP, Maurer D, Stingl G. The high affinity receptor for IgE is the predominant IgE- binding structure in lesional skin of atopic dermatitis patients. J Invest Dermatol 1997; 108: 336-342.
78. Kinet JP. The high-affinity IgE receptor (FceRI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931-972.
79. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7: 365-378.
80. Sigalov AB. Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 2004; 25: 583-589.
81. Kraft S, Wessendorf JHM, Hanau D, Bieber T. Regulation of the high affinity receptor for IgE on human epidermal Langerhans cells. J Immunol 1998; 161: 1000-1006.
82. Bieber T. Fc epsilon RI on human epidermal Langerhans cells: an old receptor with new structure and functions. Int Arch Allergy Immunol 1997; 113: 30-34.
83. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985; 65: 102-105.
84. Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest 2006; 116: 1150-1158.
85. Maurer D, Ebner C, Reininger B, Petzelbauer P, Fiebiger E, Stingl G. Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells. Adv Exp Med Biol 1997; 417: 175-178. (Pubitemid 27427739)